Accéder au contenu
Merck
Toutes les photos(1)

Documents

N6037

Sigma-Aldrich

Neridronate

≥97% (NMR), solid, bone resorption inhibitor

Synonyme(s) :

6-Amino-1-hydroxyhexylidene bisphosphonic acid, Neridronic acid, Nerixia

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C6H17NO7P2
Numéro CAS:
79778-41-9
Poids moléculaire :
277.15
Numéro MDL:
MFCD00866995
Code UNSPSC :
51111800
ID de substance PubChem :
24724553
Nomenclature NACRES :
NA.77

product name

Neridronate, ≥97% (NMR), solid

Description

may contain <1% (w/w) inorganic salts

Niveau de qualité

100

Pureté

≥97% (NMR)

Forme

solid

Couleur

white

Solubilité

H2O: >5 mg/mL

Température de stockage

2-8°C

Chaîne SMILES 

NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C6H17NO7P2/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14)

Clé InChI

PUUSSSIBPPTKTP-UHFFFAOYSA-N

Actions biochimiques/physiologiques

Neridronate is a bone resorption inhibitor. It is used to treat Osteogenesis Imperfecta, an "orphan disease" characterized by a fragility of the bone enough to be named the "illness of bones of crystal".

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 4

1 of 4

Etidronate disodium hydrate &#8805;97% (NMR), solid

Sigma-Aldrich

P5248

Etidronate disodium hydrate

Alendronate Sodium Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1599

Alendronate Sodium

Zoledronic acid monohydrate &#8805;98% (HPLC)

Sigma-Aldrich

SML0223

Zoledronic acid monohydrate

Zoledronic acid United States Pharmacopeia (USP) Reference Standard

USP

1724827

Zoledronic acid

Massimo Varenna et al.
Rheumatology (Oxford, England), 52(3), 534-542 (2012-12-04)
Complex regional pain syndrome type I (CRPS-I) is a severely disabling pain syndrome for which no definite treatment has been established. The aim of this multi-centre, randomized, double-blind placebo-controlled trial was to test the efficacy of the amino-bisphosphonate neridronate in
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 26(3), 512-518 (2010-09-04)
Aminobisphosphonates actually represent the most common treatment for Paget disease of bone (PDB). In a previous study we demonstrated that either zoledronic acid (4 mg) or neridronate (200 mg) given as a single intravenous infusion showed a similar short-term efficacy
Daniela Merlotti et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 22(10), 1510-1517 (2007-07-04)
This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in
Imène Chebbi et al.
International journal of pharmaceutics, 383(1-2), 116-122 (2009-09-15)
Bisphosphonates have been used for decades in the standard therapy of bone-related diseases, including bone metastasis of various malignancies, and they might as well be toxic on early cancer cells themselves. In order to allow a better delivery of neridronate
Gian Luca Forni et al.
British journal of haematology, 158(2), 274-282 (2012-05-11)
Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu)
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique